LOS ANGELES, Aug. 7 /PRNewswire-FirstCall/ -- Response Genetics, Inc. today announced that it will conduct a two-year research study to develop a diagnostic test kit for pancreatic cancer.
The study will combine patient outcomes data with genetic information that it extracts from archival formalin-fixed paraffin-embedded (FFPE) pancreatic tissue samples. The results could potentially lead to the development of assays and diagnostic tests for pancreatic cancer.
The study will be conducted in collaboration with UCSF, which will provide the tissue samples. Response Genetics will assume the administrative costs of the research.
Margaret A. Tempero, Deputy Director, UCSF Comprehensive Cancer Center, and Professor, Division of Medical Oncology, UCSF Department of Medicine, will serve as Principal Investigator of the project.
"We are delighted to be collaborating with Dr. Tempero, one of the nation's leading experts in pancreatic cancer, on this very important research project," said Kathleen Danenberg, President and CEO of Response Genetics. "Diagnostics tests emerging from this collaboration would help physicians tailor treatment to the individual by using genetic information to identify patients who would most benefit from surgery or chemotherapy and radiation."
Pancreatic cancer is the fifth-leading cause of cancer deaths in the United States. According to the American Cancer Society, approximately 37,170 people in the United States will be diagnosed with pancreatic cancer this year and an estimated 33,370 deaths will occur from pancreatic cancer this year in the United States.
About Response Genetics, Inc.
Response Genetics, Inc. ("RGI") is engaged in the research and development of pharmacogenomic cancer diagnostic tests based on its proprietary and patented technologies. RGI's technologies enable extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin embedded specimens. RGI currently generates revenue primarily from the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens to the pharmaceutical industry. The company was founded in 1999 and its principal headquarters are located in Los Angeles, California. For more information, please visit www.responsegenetics.com.
Forward Looking Statement Notice
Except for the historical information contained herein, this press release and the statements of representatives of Response Genetics, Inc. (the "Company") related thereto contain or may contain, among other things, certain forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions, such as the ability of the Company to analyze pancreatic cancer samples, the potential for using the results of this research to develop diagnostic tests for pancreatic cancer, the usefulness of genetic information to tailor treatment to patients, and other statements identified by words such as "projects", "may", "could", "would", "should", "believes", "expects", "anticipates", "estimates", "intends", "plans" or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission. Actual results, including, without limitation, actual sales results, if any, or the application of funds, may differ from those set forth in the forward-looking statements. These forward- looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control). The Company undertakes no obligation to publicly update forward-looking statements, whether because of new information, future events or otherwise, except as required by law.
Response Genetics, Inc.CONTACT: Investor Relations, Christine Yang of Trout Group,+1-646-378-2929; Media Relations, Dan Budwick of BMC Communications,+1-212-477-9007, x14, both for Response Genetics, Inc.
Web site: http://www.responsegenetics.com//
